CSR Profile of Novo Nordisk

Novo Nordisk is the world leader in diabetes care and has leading positions within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. With more than 29,300 employees in 76 countries, Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Novo Nordisk's value-based approach to doing business drives performance and enhances shareholder value. The Triple Bottom Line principle expresses Novo Nordisk's commitment to sustainable development and balanced growth, and is consistent with the principles of the United Nations Global Compact. Through this approach, the company seeks to build its business in a way that is financially, environmentally and socially responsible. Decision-making seeks to balance short-term gains with long-term profitability and shareholder return with other stakeholder interests.

---

CSR Press Releases, Events & Reports Comments